Mindwalk Holdings CORP. (HYFT) — SEC Filings

Q: What are the key financial highlights for Mindwalk Holdings CORP.?

Key financial highlights for Mindwalk Holdings CORP. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: What is the investment thesis for HYFT?

The investment thesis for HYFT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings filed by Mindwalk Holdings CORP..

Q: Who are the key executives at Mindwalk Holdings CORP.?

Key executives at Mindwalk Holdings CORP. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Mindwalk Holdings CORP. stock?

Risk factors for Mindwalk Holdings CORP. (HYFT) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Mindwalk Holdings CORP.?

Forward-looking statements and predictions from Mindwalk Holdings CORP. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Mindwalk Holdings CORP.. Recent 6-K filing on Dec 15, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Mindwalk Holdings CORP. on SEC EDGAR

Overview

Mindwalk Holdings CORP. (HYFT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 15, 2025: MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a Form 6-K on December 15, 2025, to report its earnings release dated December 15, 2025. The company, incorporated in A1 and headquartered in Victoria, British Columbia, operates in the Pharmaceutical Preparations sector.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant filing sentiment for Mindwalk Holdings CORP. is neutral.

Filing Type Overview

Mindwalk Holdings CORP. (HYFT) has filed 49 6-K, 1 20-F/A with the SEC between Oct 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

MindWalk Holdings Corp. Files 6-K with Earnings Release — 6-K · Dec 15, 2025 Risk: low
MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a Form 6-K on December 15, 2025, to report its earnings release dated December 15, 2025.
6-K Filing — 6-K · Dec 8, 2025
MindWalk Holdings Corp. Files 6-K with Nov 13 Press Release — 6-K · Nov 13, 2025 Risk: low
MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a Form 6-K on November 13, 2025, reporting a press release dated November 13, 2025. The c
6-K Filing — 6-K · Nov 7, 2025
MindWalk Holdings Corp. Files 6-K with Executive Comp Update — 6-K · Nov 6, 2025 Risk: low
MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a Form 6-K on November 6, 2025. This report includes a revised Statement of Executive Com
MindWalk Holdings Corp. Files 6-K with Press Release — 6-K · Oct 21, 2025 Risk: low
MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a Form 6-K on October 21, 2025, reporting a press release dated October 21, 2025. The com
MindWalk Holdings Corp. Files 6-K Report — 6-K · Oct 15, 2025 Risk: low
MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a Form 6-K on October 15, 2025, reporting information as of that date. The filing include
MindWalk Holdings Corp. Files 6-K with Pro Forma Financials — 6-K · Oct 14, 2025 Risk: low
MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a Form 6-K on October 14, 2025, reporting for the month of October 2025. The filing inclu
MindWalk Holdings Corp. Files 6-K with October Press Release — 6-K · Oct 9, 2025 Risk: low
MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a Form 6-K on October 9, 2025, reporting on its activities for the month of October 2025.
MindWalk Holdings Corp. Files 6-K Report — 6-K · Sep 22, 2025 Risk: low
MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a Form 6-K on September 22, 2025, reporting on its activities for the month of September
MindWalk Holdings Corp. Files 6-K with Financial Data — 6-K · Sep 15, 2025 Risk: low
MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a 6-K report on September 15, 2025, for the period ending July 31, 2025. The filing inclu
MindWalk Holdings Corp. Files 6-K, Reports Press Release — 6-K · Sep 10, 2025 Risk: low
MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a Form 6-K on September 10, 2025, reporting a press release dated September 10, 2025. The
ImmunoPrecise Antibodies Ltd. Files Form 6-K — 6-K · Sep 3, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on September 3, 2025, reporting a press release dated September 3, 2025. The filing indicates the company is a fo
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Sep 2, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on September 2, 2025, reporting on activities for the month of September 2025. The filing includes a press releas
ImmunoPrecise Antibodies Ltd. Files 6-K — 6-K · Aug 27, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on August 27, 2025, reporting a press release dated August 27, 2025. The filing indicates the company is a foreig
ImmunoPrecise Antibodies Ltd. Files Form 6-K — 6-K · Aug 6, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on August 6, 2025, reporting a press release dated August 6, 2025. The filing indicates the company is a foreign
ImmunoPrecise Antibodies Ltd. Files 6-K for Meeting Notice — 6-K · Aug 1, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on August 1, 2025, to report a Notice of Meeting and Record Date dated August 1, 2025. The company, with its prin
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Jul 29, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on July 29, 2025, to report a press release dated July 29, 2025. The company, headquartered in Austin, Texas, is
ImmunoPrecise Antibodies Ltd. Files 6-K — 6-K · Jul 24, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on July 24, 2025, reporting a press release dated July 24, 2025. The filing indicates the company is a foreign pr
ImmunoPrecise Antibodies Ltd. Files 6-K — 6-K · Jul 21, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on July 21, 2025, to report a press release dated July 21, 2025. The filing does not contain specific financial f
ImmunoPrecise Antibodies Ltd. Files 6-K with Press Release — 6-K · Jul 14, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on July 14, 2025, to report a press release dated July 14, 2025. The filing indicates the company is a foreign pr
ImmunoPrecise Antibodies Ltd. Files Form 6-K — 6-K · Jul 7, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on July 7, 2025, reporting a press release dated July 7, 2025. The filing indicates the company is a foreign priv
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Jul 3, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on July 3, 2025, to report a press release dated July 3, 2025. The filing does not contain specific financial fig
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Jun 24, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on June 24, 2025, to report a press release dated June 24, 2025. The filing does not contain specific financial f
ImmunoPrecise Antibodies Files 6-K with Press Release — 6-K · Jun 12, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on June 12, 2025, reporting a press release dated June 12, 2025. The filing indicates the company is a foreign pr
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Jun 5, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on June 5, 2025, to report a press release dated June 5, 2025. The filing indicates the company is a foreign priv
ImmunoPrecise Antibodies Files 6-K with Press Release — 6-K · May 21, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on May 21, 2025, to report a press release dated May 21, 2025. The filing indicates the company is a foreign priv
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · May 12, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on May 12, 2025, reporting a press release dated May 12, 2025. The filing indicates the company is a foreign priv
ImmunoPrecise Antibodies Ltd. Files Form 6-K — 6-K · Apr 11, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on April 11, 2025, reporting a press release dated April 11, 2025. The filing indicates the company is a foreign
ImmunoPrecise Antibodies Ltd. Files 6-K with SEC — 6-K · Apr 10, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on April 10, 2025, incorporating by reference several press releases and a registration statement. The filing inc
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Mar 28, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a 6-K report on March 28, 2025, for the period ending January 31, 2025. The filing includes financial data related to variou
ImmunoPrecise Antibodies Ltd. Files 6-K with Press Release — 6-K · Mar 13, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on March 13, 2025, incorporating a press release dated March 13, 2025, as Exhibit 99.1. This filing is related to
ImmunoPrecise Antibodies Ltd. Files 6-K with Press Release — 6-K · Mar 12, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on March 12, 2025, incorporating a press release dated March 12, 2025, as Exhibit 99.1. This filing is incorporat
ImmunoPrecise Antibodies Ltd. Files 6-K with Press Release — 6-K · Feb 24, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on February 24, 2025, incorporating a press release dated February 24, 2025, as Exhibit 99.1. This filing is rela
ImmunoPrecise Antibodies Ltd. Clarifies Share Count — 6-K · Feb 3, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed an amendment to its January 2025 Form 6-K on February 3, 2025. The amendment's sole purpose is to add a sentence to a previo
ImmunoPrecise Antibodies Files 6-K with Press Release — 6-K · Jan 27, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on January 27, 2025, reporting a press release dated January 27, 2025. The filing indicates the company is a fore
ImmunoPrecise Antibodies Ltd. Files 6-K with Press Release — 6-K · Jan 22, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on January 22, 2025, to report a press release dated January 22, 2025. The filing indicates the company is a fore
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Jan 17, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on January 17, 2025, reporting on its activities for the month of January 2025. The filing includes a press relea
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Jan 3, 2025 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on January 3, 2025, incorporating by reference a Material Change Report dated January 2, 2025. This filing is rel
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Dec 23, 2024 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on December 23, 2024, to report information for the month of December 2024. The filing includes a press release d
ImmunoPrecise Antibodies Ltd. Files 20-F/A Amendment — 20-F/A · Dec 10, 2024 Risk: medium
ImmunoPrecise Antibodies Ltd. filed an amendment (20-F/A) to its annual report for the fiscal year ended April 30, 2024. The filing, dated December 10, 2024, pr
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Dec 3, 2024 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on December 3, 2024, to report a press release dated December 3, 2024. The filing does not contain specific finan
ImmunoPrecise Antibodies Ltd. Files AGM Voting Results — 6-K · Nov 18, 2024 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on November 18, 2024, reporting voting results from their AGM held on November 15, 2024. The filing incorporates
ImmunoPrecise Antibodies Ltd. Files 6-K with Press Release — 6-K · Nov 13, 2024 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on November 13, 2024, to report a press release dated November 13, 2024. The filing indicates the company is a fo
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Nov 4, 2024 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on November 4, 2024, to report a press release dated November 4, 2024. The filing does not contain specific finan
ImmunoPrecise Antibodies Ltd. Files Form 6-K — 6-K · Oct 28, 2024 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on October 28, 2024, to report a press release dated October 28, 2024. The filing indicates the company is a fore
ImmunoPrecise Antibodies Ltd. Files October 2024 6-K Report — 6-K · Oct 24, 2024 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on October 24, 2024, reporting for the month of October 2024. The filing was signed by Kristin Taylor, Chief Fina
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Oct 21, 2024 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on October 21, 2024, to report a press release dated October 21, 2024. The filing does not contain specific finan
ImmunoPrecise Antibodies Ltd. Files Form 6-K — 6-K · Oct 11, 2024 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on October 11, 2024, reporting for the month of October 2024. The filing includes an Amended Notice of Annual Gen
ImmunoPrecise Antibodies Ltd. Files 6-K Report — 6-K · Oct 10, 2024 Risk: low
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on October 10, 2024, to report a press release dated October 10, 2024. The filing indicates the company is a fore

Risk Profile

Risk Assessment: Of HYFT's 48 recent filings, 0 were flagged as high-risk, 1 as medium-risk, and 47 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Jennifer Bath
Kristin Taylor

Top Tags

press-release (33) · filing (18) · reporting (10) · sec-filing (9) · foreign-private-issuer (8) · 6-K (8) · regulatory-filing (5) · filing-update (4) · company-update (3) · financial-reporting (3)

Key Numbers

Commission File Number: 001-39530 — Identifies the specific SEC filing for MindWalk Holdings Corp.
SEC File Number: 001-39530 — Identifies the company's filing with the SEC.
Exhibit Number: 99.1 — Contains Unaudited Pro Forma Condensed Consolidated Financial Information
Period End Date: 2025-07-31 — Latest financial reporting period
Fiscal Year End: 2025-04-30 — Company's fiscal year end
Previous Fiscal Year End: 2024-04-30 — Prior year financial comparison
Financial Data: N/A — Specific dollar amounts for assets like vehicles and computer hardware are detailed within the filing.
Employee Data: N/A — Information related to employees and options is included.
Common Shares Outstanding: 45,765,118 — This is the updated and clarified number of shares issued and outstanding as of the filing date.
Filing Date: 20241210 — Date the amendment was submitted to the SEC.

Related Companies

MWC

Frequently Asked Questions

What are the latest SEC filings for Mindwalk Holdings CORP. (HYFT)?

Mindwalk Holdings CORP. has 50 recent SEC filings from Oct 2024 to Dec 2025, including 49 6-K, 1 20-F/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of HYFT filings?

Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant sentiment is neutral.

Where can I find Mindwalk Holdings CORP. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Mindwalk Holdings CORP. (HYFT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Mindwalk Holdings CORP.?

Financial highlights for Mindwalk Holdings CORP. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for HYFT?

Investment thesis data for HYFT will be available once enriched filings are processed.

Who are the key executives at Mindwalk Holdings CORP.?

Key executives identified across Mindwalk Holdings CORP.'s filings include Jennifer Bath, Kristin Taylor.

What are the main risk factors for Mindwalk Holdings CORP. stock?

Of HYFT's 48 assessed filings, 0 were flagged high-risk, 1 medium-risk, and 47 low-risk.

What are recent predictions and forward guidance from Mindwalk Holdings CORP.?

Forward guidance and predictions for Mindwalk Holdings CORP. are extracted from SEC filings as they are enriched.